Novartis’ breakthrough malaria treatment for newborns offers safer, infant-friendly care, closing a critical gap in protecting the most vulnerable group from this deadly disease.
- Novartis introduces the first approved malaria treatment for newborns and young infants
- Safer dosing helps lower the risk of overdose and toxicity
- Protects millions of babies born in malaria-endemic regions each year
Novartis has announced a major breakthrough in the fight against malaria with the approval of Coartem® Baby (artemether-lumefantrine), the first antimalarial medicine specially developed for newborns and young infants. Swissmedic, the Swiss agency for therapeutic products, granted the approval, paving the way…
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We 5guruayurveda.com want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on. For any glitch kindly connect at 5guruayurveda.com
